Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057577
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2003-04-04
Brief Title:
Prevention of Recurrence in Depression With Drugs and CT
Sponsor:
Vanderbilt University
Organization:
Vanderbilt University
Study Overview
Official Title:
Prevention of Recurrence in Depression With Drugs and CT
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CPT3
Brief Summary:
This study will determine whether the addition of Cognitive Therapy CT to antidepressant medication ADM enhances treatment for depression This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over
Detailed Description:
It is commonly believed that the combination of ADM and psychotherapy is more effective in treating depression than either treatment alone Data indicate that CT enhances the initial effects of ADM but little research has been conducted to determine whether prior exposure to CT prevents the onset of new depressive episodes This study will determine the effectiveness of adding CT to ADM for the treatment of depression
Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery At recovery patients receiving combined treatment discontinue cognitive therapy all recovered patients are randomized a second time to either maintenance medication or medication withdrawal Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms
Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery At recovery patients receiving combined treatment discontinue cognitive therapy all recovered patients are randomized a second time to either maintenance medication or medication withdrawal Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH060713 | NIH | None | httpsreporternihgovquickSearchR01MH060713 |